These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32531682)

  • 21. 3-Hydrazinoindolin-2-one derivatives: Chemical classification and investigation of their targets as anticancer agents.
    Ibrahim HS; Abou-Seri SM; Abdel-Aziz HA
    Eur J Med Chem; 2016 Oct; 122():366-381. PubMed ID: 27391135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of 2-aryl-2-(3-indolyl)acetohydroxamates against drug-resistant cancer cells.
    Aksenov AV; Smirnov AN; Magedov IV; Reisenauer MR; Aksenov NA; Aksenova IV; Pendleton AL; Nguyen G; Johnston RK; Rubin M; De Carvalho A; Kiss R; Mathieu V; Lefranc F; Correa J; Cavazos DA; Brenner AJ; Bryan BA; Rogelj S; Kornienko A; Frolova LV
    J Med Chem; 2015 Mar; 58(5):2206-20. PubMed ID: 25671501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medicinal Perspective of Indole Derivatives: Recent Developments and Structure-Activity Relationship Studies.
    Kumar D; Sharma S; Kalra S; Singh G; Monga V; Kumar B
    Curr Drug Targets; 2020; 21(9):864-891. PubMed ID: 32156235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preliminary SAR on indole-3-carbinol and related fragments reveals a novel anticancer lead compound against resistant glioblastoma cells.
    Sherer C; Tolaymat I; Rowther F; Warr T; Snape TJ
    Bioorg Med Chem Lett; 2017 Apr; 27(7):1561-1565. PubMed ID: 28256372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, and structure-activity relationships of pyrimido[4,5-b]indole-4-amines as microtubule depolymerizing agents that are effective against multidrug resistant cells.
    Devambatla RKV; Li W; Zaware N; Choudhary S; Hamel E; Mooberry SL; Gangjee A
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3423-3430. PubMed ID: 28610978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The anti-breast cancer potential of indole/isatin hybrids.
    Wang R; Huang R; Yuan Y; Wang Z; Shen K
    Arch Pharm (Weinheim); 2023 Nov; 356(11):e2300402. PubMed ID: 37650315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoterpene indole alkaloid azine derivatives as MDR reversal agents.
    Paterna A; Khonkarn R; Mulhovo S; Moreno A; Madeira Girio P; Baubichon-Cortay H; Falson P; Ferreira MU
    Bioorg Med Chem; 2018 Jan; 26(2):421-434. PubMed ID: 29233614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis, and biological evaluation of novel 1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide analogs in MCF-7 and MDA-MB-468 breast cancer cell lines.
    Kim YJ; Pyo JS; Jung YS; Kwak JH
    Bioorg Med Chem Lett; 2017 Feb; 27(3):607-611. PubMed ID: 27993518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent Advances in β-lactam Derivatives as Potential Anticancer Agents.
    Zhang X; Jia Y
    Curr Top Med Chem; 2020; 20(16):1468-1480. PubMed ID: 32148196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ferrocene-containing hybrids as potential anticancer agents: Current developments, mechanisms of action and structure-activity relationships.
    Wang R; Chen H; Yan W; Zheng M; Zhang T; Zhang Y
    Eur J Med Chem; 2020 Mar; 190():112109. PubMed ID: 32032851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and antiproliferative activity of a novel class of indole-2-carboxylate derivatives.
    Ji XY; Xue ST; Zhan YC; Shen JJ; Wu LT; Jin J; Wang Z; Li ZR
    Eur J Med Chem; 2014 Aug; 83():409-18. PubMed ID: 24996136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic Review on Cytotoxic and Anticancer Potential of N-Substituted Isatins as Novel Class of Compounds Useful in Multidrug-Resistant Cancer Therapy: In Silico and In Vitro Analysis.
    Gupta AK; Tulsyan S; Bharadwaj M; Mehrotra R
    Top Curr Chem (Cham); 2019 May; 377(3):15. PubMed ID: 31073777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol.
    Arora A; Seth K; Kalra N; Shukla Y
    Toxicol Appl Pharmacol; 2005 Feb; 202(3):237-43. PubMed ID: 15667829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lenvatinib-zinc phthalocyanine conjugates as potential agents for enhancing synergistic therapy of multidrug-resistant cancer by glutathione depletion.
    Wei G; Huang L; Jiang Y; Shen Y; Huang Z; Huang Y; Sun X; Zhao C
    Eur J Med Chem; 2019 May; 169():53-64. PubMed ID: 30856406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in isatin hybrids as potential anticancer agents.
    Ding Z; Zhou M; Zeng C
    Arch Pharm (Weinheim); 2020 Mar; 353(3):e1900367. PubMed ID: 31960987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, mechanistic and histopathological studies of small-molecules of novel indole-2-carboxamides and pyrazino[1,2-a]indol-1(2H)-ones as potential anticancer agents effecting the reactive oxygen species production.
    Youssif BGM; Abdelrahman MH; Abdelazeem AH; Abdelgawad MA; Ibrahim HM; Salem OIA; Mohamed MFA; Treambleau L; Bukhari SNA
    Eur J Med Chem; 2018 Feb; 146():260-273. PubMed ID: 29407956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isatin-azole hybrids and their anticancer activities.
    Hou Y; Shang C; Wang H; Yun J
    Arch Pharm (Weinheim); 2020 Jan; 353(1):e1900272. PubMed ID: 31691360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3).
    Ban F; Leblanc E; Li H; Munuganti RS; Frewin K; Rennie PS; Cherkasov A
    J Med Chem; 2014 Aug; 57(15):6867-72. PubMed ID: 25025737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis of novel indole derivatives as promising DNA-binding agents and evaluation of antitumor and antitopoisomerase I activities.
    Lafayette EA; de Almeida SMV; Cavalcanti Santos RV; de Oliveira JF; Amorim CADC; da Silva RMF; Pitta MGDR; Pitta IDR; de Moura RO; de Carvalho Júnior LB; de Melo Rêgo MJB; de Lima MDCA
    Eur J Med Chem; 2017 Aug; 136():511-522. PubMed ID: 28531811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of Multidrug-Resistant Leukemia Cells by Novel Artemisinin-, Egonol-, and Thymoquinone-Derived Hybrid Compounds.
    Gruber L; Abdelfatah S; Fröhlich T; Reiter C; Klein V; Tsogoeva SB; Efferth T
    Molecules; 2018 Apr; 23(4):. PubMed ID: 29642419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.